On March 31, 2026, the Center for Drug Evaluation of China’s National Medical Products Administration delivered exciting news: GFH375, developed by GenFleet Therapeutics, has been officially included as a “Breakthrough Therapy” candidate for the treatment of patients with metastatic pancreatic cancer harboring the KRAS G12D mutation who have received at least one prior systemic therapy. This marks a critical step forward in the field of precision therapy for pancreatic cancer.
If you or a loved one is struggling with advanced KRAS G12D-mutant pancreatic cancer, do not lose hope. The Beijing South Region Oncology Hospital International Department (400-880-3716) is closely following this cutting-edge development and offers professional consultation and treatment coordination services for international patients.
**About GFH375/VS-7375**
GFH375 is an orally active, potent, and highly selective small-molecule KRAS G12D (ON/OFF) inhibitor designed to target GTP/GDP exchange, thereby disrupting downstream pathway activation and effectively inhibiting tumor cell proliferation. Preclinical studies demonstrated dose-dependent inhibition in models bearing KRAS G12D mutations; GFH375 also showed low off-target risk in kinase selectivity and safety target assays.
GenFleet entered into a discovery and development collaboration with Verastem Oncology (Nasdaq: VSTM) to advance three novel oncology programs targeting RAS/MAPK pathway-driven cancers. The collaboration grants Verastem an exclusive option to obtain a license for each of the three compounds after successful completion of predetermined milestones in a Phase I trial. In December 2023, Verastem selected GFH375/VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, as its lead program from the collaboration, and the license for GFH375 exercised in January 2025 was the first from this collaboration. The licenses grant Verastem development and commercial rights outside of China, while GenFleet retains rights within China.
**Promising Phase I/II clinical trial data presented at the 2025 ESMO Congress:**
- 91.5% of patients experienced reduction in target lesions
- Objective response rate (ORR) reached 40.7%
- Disease control rate (DCR) was as high as 96.7%
- Median progression-free survival (mPFS) was 5.52 months
- 4-month progression-free survival rate was 78.2%
These data, derived from 59 patients with advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) who had received prior systemic therapy, strongly demonstrate the potent anti-tumor activity of GFH375 in refractory pancreatic cancer.
**Why Choose Beijing South Region Oncology Hospital International Department?**
As a pioneer in international medical services, the Beijing South Region Oncology Hospital International Department is committed to providing global patients with:
- Multilingual professional medical consultation and appointment services
- Access to leading oncology experts both in China and internationally
- One-stop green channel for cross-border medical treatment
We understand that for patients with advanced cancer, every additional day of waiting brings greater risk. Therefore, we have established multiple convenient international contact channels to ensure you receive timely professional support.
**Contact us today and begin your journey of hope**
��� Hotline: 400-880-3716
��� WeChat: 17801183037
��� Email:
- 100085_010@163.com
- myimmnet@163.com
No matter which country or region you are in, or how many treatment options you have already tried, the Beijing South Region Oncology Hospital International Department is ready to stand with you in your fight against cancer. The breakthrough progress of GFH375 may be the light you have been waiting for.
Call 400-880-3716, add us on WeChat at 17801183037, or email us at 100085_010@163.com or myimmnet@163.com.
Together, let us strive for more possibilities for life.
> Note: GFH375 has not yet been officially approved for marketing in mainland China. Its Breakthrough Therapy designation is expected to accelerate clinical accessibility. The Beijing South Region Oncology Hospital International Department will closely monitor progress in drug accessibility and provide information on cutting-edge treatments and coordination services for eligible patients. Please follow your physician’s guidance regarding specific treatment plans.
Post time: Apr-10-2026